Journal of Cardiovascular Pharmacology最新文献_第9页

Short-Term Effect of Levosimendan in Acute Right Heart Failure Caused by Pulmonary Hypertension: A Pilot Study. 左西孟旦对肺动脉高压引起的急性右心衰的短期疗效：一项初步研究。

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-06-01 DOI: 10.1097/FJC.0000000000001824

Yu-Qiang Wang, Qing-Yue Deng, Zhi-Zhong Zhang, Gao-Lin Wang, Zhen Zhao, Chen-Fen Su, Li Wang, Xu Ge, Guo-Xing Wang, Hongli Xiao

{"title":"Short-Term Effect of Levosimendan in Acute Right Heart Failure Caused by Pulmonary Hypertension: A Pilot Study.","authors":"Yu-Qiang Wang, Qing-Yue Deng, Zhi-Zhong Zhang, Gao-Lin Wang, Zhen Zhao, Chen-Fen Su, Li Wang, Xu Ge, Guo-Xing Wang, Hongli Xiao","doi":"10.1097/FJC.0000000000001824","DOIUrl":"10.1097/FJC.0000000000001824","url":null,"abstract":"Abstract: Pulmonary hypertension (PH) causes right heart failure (RHF), leading to an unfavorable prognosis. This prospective single-arm study evaluated the acute effects of levosimendan in 105 patients with RHF secondary to PH. Levosimendan was administered as a continuous infusion at a rate of 0.1 μg/kg/min over 24 hours. The primary end point was improvement in WHO Functional Class (WHO-FC) at day 7, with secondary end points including the Borg dyspnea scores, systolic pulmonary artery pressure (SPAP), and echocardiographic parameters. Treatment resulted in significant clinical and hemodynamic improvements by day 7. WHO-FC decreased from a median of 4.00 (3.00, 4.00) to 3.00 (2.00, 3.00) ( P < 0.001) and Borg dyspnea scores improved from 8.00 (6.00, 8.00) to 4.00 (4.00, 5.00) ( P < 0.001). SPAP decreased significantly from 57.51 (51.24, 68.00) mm Hg to 50.16 (44.55, 59.83) mm Hg ( P = 0.002). Echocardiography showed favorable changes, including reduced left ventricular end-systolic volume and tricuspid regurgitation velocity, alongside increased left ventricular fractional shortening. In a subgroup with left heart disease, left ventricular ejection fraction increased from 33.10% (27.58, 47.20) to 36.50% (30.63, 49.50) ( P = 0.025). Patients with heart failure with preserved ejection fraction also showed reduced SPAP and tricuspid regurgitation velocity. The findings suggest that levosimendan provides acute physiological benefits in PH-related RHF, with potential anti-inflammatory, hepatoprotective, and glycemic-modulating properties. Patient-specific medical history and concomitant medications may influence treatment response. This study offers preliminary evidence supporting the acute physiological effects and tolerability of levosimendan in this population.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"514-524"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147633196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac Remodeling in Preeclampsia: A Large Language Model-Assisted Meta-Analysis and Meta-Regression. 子痫前期的心脏重构：大语言模型辅助的meta分析和meta回归。

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-06-01 DOI: 10.1097/FJC.0000000000001774

Lefteris Teperikidis, Aristi Boulmpou, Ghadir Amin, Kyriakos Polymenakos, Basil Tarlatzis, Gregg W Stone, Deepak L Bhatt, Giuseppe Biondi Zoccai, George W Booz

{"title":"Cardiac Remodeling in Preeclampsia: A Large Language Model-Assisted Meta-Analysis and Meta-Regression.","authors":"Lefteris Teperikidis, Aristi Boulmpou, Ghadir Amin, Kyriakos Polymenakos, Basil Tarlatzis, Gregg W Stone, Deepak L Bhatt, Giuseppe Biondi Zoccai, George W Booz","doi":"10.1097/FJC.0000000000001774","DOIUrl":"10.1097/FJC.0000000000001774","url":null,"abstract":"Abstract: Preeclampsia is a hypertensive disorder of pregnancy associated with substantial maternal morbidity and long-term cardiovascular risk, but the consistency of echocardiographic remodeling remains unclear. We conducted a mega-meta-analysis of left ventricular function and geometry, enabled by Synthesa AI, a large language model-based suite of tools. A PROSPERO-registered review (CRD420251109103) searched PubMed, Scopus, and Embase without date limits. Synthesa AI screened more than 138,000 abstracts, extracted data, assessed risk of bias, and generated Bayesian analytic code, with all outputs validated by human reviewers. Seventy-five studies which met the eligibility criteria were included. Preeclampsia was associated with a small but statistically significant reduction in ejection fraction (mean difference -0.87%, 95% CrI, -1.58 to -0.16) and a clinically meaningful impairment in global longitudinal strain (-3.08%, 95% CrI, -4.13 to -2.06). Left ventricular mass index was substantially higher in the preeclampsia group (+13.10 g/m 2 , 95% CrI, 10.06-16.21), as was relative wall thickness (+0.062, 95% CrI, 0.042-0.081), whereas fractional shortening showed no significant difference (-0.60%, 95% CrI, -2.15 to +0.86). Moderator analyses revealed that BMI and parity significantly influenced strain, whereas gestational age at diagnosis accounted for nearly all variance in ventricular mass. This mega-meta-analysis defines a remodeling phenotype of preserved ejection fraction with hypertrophic adaptation and impaired strain consistent with subclinical systolic dysfunction. Equally, it demonstrates the transformative role of LLM-based tools, showing that evidence syntheses of this magnitude can be automated, scaled, and standardized in ways previously unattainable.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"403-419"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145549454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Colchicine for Major Adverse Cardiovascular Events: An Updated ChatGPT-Assisted Systematic Review and Meta-Analysis. 秋水仙碱治疗主要心血管不良事件：一项最新的chatgpt辅助系统评价和荟萃分析。

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-06-01 DOI: 10.1097/FJC.0000000000001780

Lefteris Teperikidis, Aristi Boulmpou, Manisha Chownk, Rohan Jagdale, George W Booz, Giuseppe Biondi-Zoccai, Deepak L Bhatt

{"title":"Colchicine for Major Adverse Cardiovascular Events: An Updated ChatGPT-Assisted Systematic Review and Meta-Analysis.","authors":"Lefteris Teperikidis, Aristi Boulmpou, Manisha Chownk, Rohan Jagdale, George W Booz, Giuseppe Biondi-Zoccai, Deepak L Bhatt","doi":"10.1097/FJC.0000000000001780","DOIUrl":"10.1097/FJC.0000000000001780","url":null,"abstract":"Abstract: Colchicine has been studied as an anti-inflammatory treatment for cardiovascular prevention, but findings from randomized trials have been inconsistent. This meta-analysis evaluated the efficacy and safety of colchicine in reducing major adverse cardiovascular events (MACE) and its individual components, using ChatGPT as an assistant throughout the process. Randomized trials of colchicine for cardiovascular prevention were systematically identified, and data extraction, risk of bias assessment, and meta-analyses were performed with ChatGPT under human supervision. The primary outcome was MACE, while secondary outcomes included myocardial infarction (MI), stroke, revascularization, cardiovascular mortality, and all-cause mortality. Eleven trials involving 30,888 patients were included. Colchicine significantly reduced MACE (risk ratio (RR) 0.75, 95% CI, 0.63-0.88) and MI (RR 0.82, 95% CI 0.70-0.96), though no significant effects were observed for stroke, cardiovascular mortality, or all-cause mortality. In addition to its clinical findings, this study illustrates the potential of ChatGPT to assist in systematic reviews and meta-analyses by automating screening, data extraction, bias assessment, and statistical code generation. This integration reduced researcher time by >70% while maintaining accuracy through human validation. Overall, colchicine seems to lower the risk of MACE but the results of the CLEAR trial have lowered certainty, while the findings highlight the feasibility and efficiency gains of using large language models in evidence synthesis workflows.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"420-431"},"PeriodicalIF":2.5,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145774845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expert Opinion: Restrictions, Precautions, or Normalcy? Defining Everyday Risk in Patients Treated With IL-1 Blockers for Recurrent Pericarditis. 专家意见：限制、预防还是正常？定义复发性心包炎患者接受IL-1阻滞剂治疗的日常风险

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-05-26 DOI: 10.1097/FJC.0000000000001837

Patrick Creechan, Jonathan Salik, Brittany Weber, Taryn Youngstein, Antonio Abbate, Allan Klein, Syed Waqas Haider

引用次数: 0

Diurnal Rhythm in Blood Pressure Is Preserved in Hypertensive Mice Despite Therapy With Mineralocorticoid Receptor Antagonists. 尽管使用矿皮质激素受体拮抗剂治疗，高血压小鼠的血压昼夜节律仍保持不变。

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-05-01 DOI: 10.1097/FJC.0000000000001812

Diana S Usai, Olga Kudryavtseva, Morten B Thomsen

{"title":"Diurnal Rhythm in Blood Pressure Is Preserved in Hypertensive Mice Despite Therapy With Mineralocorticoid Receptor Antagonists.","authors":"Diana S Usai, Olga Kudryavtseva, Morten B Thomsen","doi":"10.1097/FJC.0000000000001812","DOIUrl":"10.1097/FJC.0000000000001812","url":null,"abstract":"Abstract: Human arterial blood pressure follows a circadian rhythm, where pressure is highest during the day and lowest during the night. Patients with hypertension can have either a preserved rhythm or a dampened rhythm with a lower day-to-night difference, called \"dippers\" and \"nondippers,\" respectively. Spironolactone, eplerenone, and the newer finerenone are mineralocorticoid receptor antagonists (MRAs) used for patients with resistant hypertension. In this study, we describe the 24h diurnal cycle in blood pressure in mice with and without hypertension to test whether high blood pressure induced a nondipping phenotype. Moreover, we tested whether the 3 MRAs affected the 24h cycles in blood pressure in the mice. Radiotelemetry devices were used to monitor blood pressure continuously in freely roaming mice (n = 19). Hypertension was induced by l -nitroarginine methyl ester ( l -NAME, 1 g/L) dissolved in the drinking water. A dipping phenotype was acknowledged if the nocturnal reduction in blood pressure was >10%. The 3 MRAs were administered orally once daily. Significant 24h rhythms were identified in blood pressure and 89% of the mice had a dipping phenotype at baseline. Only 42% of the hypertensive mice were dippers ( P > 0.05 vs. baseline). The MRAs at the doses tested did not change the 24h rhythm in blood pressure, and they did not restore a dipping phenotype in the nondipping hypertensive mice. Thus, l -NAME causes hypertension in mice and induces a \"nondipper\" phenotype in most of the mice. Spironolactone, eplerenone, or finerenone at the selected doses do not change arterial blood pressure in hypertensive mice.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"337-347"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147306201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Multifaceted Role of Angiopoietin-Like Proteins in Coronary Heart Disease: From Molecular Mechanisms to Clinical Translation. 血管生成素样蛋白在冠心病中的多重作用：从分子机制到临床转化。

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-05-01 DOI: 10.1097/FJC.0000000000001815

Jie Tan, Jun Gu

{"title":"The Multifaceted Role of Angiopoietin-Like Proteins in Coronary Heart Disease: From Molecular Mechanisms to Clinical Translation.","authors":"Jie Tan, Jun Gu","doi":"10.1097/FJC.0000000000001815","DOIUrl":"10.1097/FJC.0000000000001815","url":null,"abstract":"Abstract: Coronary heart disease (CHD) remains a leading cause of cardiovascular morbidity and mortality worldwide, posing a global health threat. In recent years, angiotensin-like proteins (ANGPTLs) have emerged as a research focus in CHD because of their critical role in regulating lipid metabolism and inflammation. ANGPTLs are a class of secreted glycoproteins that primarily regulate lipid metabolism by influencing lipoprotein lipase activity. Dysfunction of these proteins leads to dyslipidemia, thereby promoting the formation of atherosclerotic plaques. In addition, ANGPTLs act as proinflammatory factors, accelerating the development of endotheliitis. Current ANGPTL-targeted therapeutic strategies (monoclonal antibodies, small interfering RNA) have advanced to clinical trial stages, demonstrating favorable safety, tolerability, and lipid-lowering effects in humans. These approaches hold promise as novel preventive and therapeutic measures for CHD. This article aims to elucidate the multifaceted role of ANGPTLs in CHD, summarize existing drug research, and outline future research directions, emphasizing the broad prospects of ANGPTL-targeted therapies in CHD prevention and treatment.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"324-336"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147344341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Design and Rationale of the COMMIT-LAD Registry: A Comprehensive Analysis of Medical and Invasive Treatment Strategies for Patients With Significant Left Anterior Descending Artery Disease (COMMIT-LAD). COMMIT-LAD登记的设计和基本原理：对严重左前降支疾病（COMMIT -LAD）患者的医学和侵入性治疗策略的综合分析。

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-05-01 DOI: 10.1097/FJC.0000000000001799

Roberto Bova, Janneke Bastings, Matteo Betti, Charlotte Snik, Samuel Heuts, Patrique Segers, Patty J C Winkler, Pieter A Vriesendorp, Elham Bidar, Jurriën M Ten Berg, Arpad Lux, Arnoud W J Van't Hof

{"title":"Design and Rationale of the COMMIT-LAD Registry: A Comprehensive Analysis of Medical and Invasive Treatment Strategies for Patients With Significant Left Anterior Descending Artery Disease (COMMIT-LAD).","authors":"Roberto Bova, Janneke Bastings, Matteo Betti, Charlotte Snik, Samuel Heuts, Patrique Segers, Patty J C Winkler, Pieter A Vriesendorp, Elham Bidar, Jurriën M Ten Berg, Arpad Lux, Arnoud W J Van't Hof","doi":"10.1097/FJC.0000000000001799","DOIUrl":"10.1097/FJC.0000000000001799","url":null,"abstract":"Abstract: Understanding the severity and anatomical pattern of coronary artery disease (CAD), particularly whether lesions are focal or diffuse, is critical in determining the most effective treatment strategy for patients with significant left anterior descending (LAD) disease. Although percutaneous coronary intervention remains the preferred treatment for focal disease, diffuse CAD presents therapeutic challenges, with options ranging from optimal medical therapy to coronary artery bypass grafting. The COMMIT LAD registry is a prospective, multicenter observational study initiated in the Netherlands in January 2024, enrolling patients with symptomatic and significant LAD disease. The registry collects longitudinal data at multiple follow-up points over 12 months. The primary aim was to assess the 1-year incidence of major adverse cardiovascular events, including cardiovascular death, myocardial infarction, stroke, or unplanned revascularization, in patients receiving either surgical or pharmacological treatment for diffuse LAD disease. Key secondary endpoints include patient-reported symptom burden and quality of life, assessed using validated questionnaires. This study provides a real-world overview of current treatment approaches to LAD disease, emphasizing differences in outcomes between diffuse and focal CAD. Despite limitations such as nonrandomized design and variability in treatment selection, COMMIT LAD offers valuable insights into practice patterns and patient experiences across centers. Findings from this registry are expected to inform clinicians about comparative outcomes and guide more tailored treatment strategies for diffuse CAD.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"357-363"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147490842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sphingosine-1-Phosphate/Protein Kinase Cβ2 Signaling Mediates Hypercontraction of Mesenteric Arterial Smooth Muscle in Spontaneously Hypertensive Rats. 鞘氨醇-1-磷酸/蛋白激酶c - β2信号传导介导自发性高血压大鼠肠系膜动脉平滑肌过度收缩

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-05-01 DOI: 10.1097/FJC.0000000000001813

Haiyan Wang, Libing Deng, Yu Shan, Aizhong Wang, Hui Zhang, Yan Wang

{"title":"Sphingosine-1-Phosphate/Protein Kinase Cβ2 Signaling Mediates Hypercontraction of Mesenteric Arterial Smooth Muscle in Spontaneously Hypertensive Rats.","authors":"Haiyan Wang, Libing Deng, Yu Shan, Aizhong Wang, Hui Zhang, Yan Wang","doi":"10.1097/FJC.0000000000001813","DOIUrl":"10.1097/FJC.0000000000001813","url":null,"abstract":"Abstract: Protein kinase C isoforms are crucial in hypertension-associated vascular dysfunction. Our previous study suggested that upregulated PKCβ2 contributed to aorta hypercontraction in spontaneously hypertensive rats (SHRs). However, its role in resistance arteries remains unclear. Considering the implications of sphingosine 1-phosphate (S1P) and its receptors (S1PRs) in hypertensive vascular dysfunction, we investigated whether PKCβ2 is regulated by S1P in SHR mesenteric arteries and elucidated its underlying mechanisms. Functional studies were performed on endothelium-denuded mesenteric arteries isolated from SHRs and Wistar-Kyoto rats. Expression of PKCβ2, S1P2, and S1P3 and phosphorylation levels of PKCβ2 and key proteins in the calcium sensitization pathway were assessed by Western blotting using mesenteric arteries and mesenteric arterial smooth muscle cells. PKCβ2 expression was significantly elevated in SHRs. LY333531, a PKCβ inhibitor, attenuated contraction induced by norepinephrine and S1P in SHRs. S1P significantly increased PKCβ2 phosphorylation in SHRs, an effect suppressed by sphingosine kinase 1 inhibitor PF-543. Inhibition or silencing of PKCβ2 significantly suppressed S1P-induced calcium sensitization. The expression levels of S1P2 and S1P3 were markedly higher in SHRs, and the inhibitory effect of LY333531 on S1P-induced contraction was not altered by JTE-013 (an S1P2 antagonist) or TY-52156 (an S1P3 antagonist). Furthermore, inhibition or silencing of S1P2 or S1P3 suppressed the activation of PKCβ2 and downstream calcium sensitization pathway. These findings demonstrate that S1P activates PKCβ2 via S1P2 and S1P3, enhancing calcium sensitization pathway and promoting hypercontraction in SHR. Thus, the S1P/PKCβ2 pathway is a potential therapeutic target for hypertensive vascular dysfunction.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"311-323"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147344312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardioprotective Effects of Prophylactic Angiotensin-Converting Enzyme Inhibitors in Anthracycline-Induced Cardiotoxicity: A Systematic Review and Meta-analysis of Randomized Trials. 预防性ACE抑制剂对蒽环类药物引起的心脏毒性的心脏保护作用：随机试验的系统回顾和荟萃分析。

IF 2.5 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-05-01 DOI: 10.1097/FJC.0000000000001814

Davide Pizzi, Luca Fazzini, David Bassil, Pooja Bajaj, Giordano M Pugliesi, Christian C Dessalvi

{"title":"Cardioprotective Effects of Prophylactic Angiotensin-Converting Enzyme Inhibitors in Anthracycline-Induced Cardiotoxicity: A Systematic Review and Meta-analysis of Randomized Trials.","authors":"Davide Pizzi, Luca Fazzini, David Bassil, Pooja Bajaj, Giordano M Pugliesi, Christian C Dessalvi","doi":"10.1097/FJC.0000000000001814","DOIUrl":"10.1097/FJC.0000000000001814","url":null,"abstract":"Abstract: This study aimed to evaluate the efficacy of angiotensin-converting enzyme inhibitors (ACEi) in preventing anthracycline-induced cardiotoxicity in patients undergoing anthracycline-based chemotherapy. PubMed, Embase, and Cochrane databases were searched for randomized controlled trials (RCTs) comparing ACEi with standard treatment/placebo for cardiotoxicity prevention in patients undergoing anthracycline-based chemotherapy. We pooled outcomes of echocardiographic and cardiac biomarker changes. A random-effects model was used for all outcomes. We included 7 RCTs with 686 patients, of whom 346 (50%) received prophylaxis with ACEi. The most common malignancy was breast cancer, and the follow-up ranged from 6 to 31 months. Prophylactic use of ACEi was associated with a significantly smaller reduction in left ventricular ejection fraction (LVEF) compared with the control group {mean difference (MD) -5% [95% confidence interval (CI) -8% to -2%]; P < 0.010}. Subgroup analysis limited to studies excluding trastuzumab from the chemotherapy regimens showed no significant difference [MD -7% (95% CI -16% to 2%); P = 0.110]. By contrast, in studies including trastuzumab-containing regimens, ACEi demonstrated a statistically significant effect in limiting LVEF reduction [MD -3%, (95% CI -4 to -1); P < 0.010]. Diastolic function (E/A ratio) changes [MD 0.0 (95% CI -0.1 to 0.09); I 2 = 36.3%] and relative risk of increased troponin I at follow-up [Risk-Ratios 0.58 (95% CI 0.17-1.94); I 2 = 69.6%] were not statistically significant. Prophylactic ACEi administration in patients undergoing anthracycline-based chemotherapy was associated with a smaller decline in LVEF. This protective role may be more relevant in patients also receiving trastuzumab. More powered and longer follow-up studies are needed to confirm these findings.","PeriodicalId":15212,"journal":{"name":"Journal of Cardiovascular Pharmacology","volume":" ","pages":"348-356"},"PeriodicalIF":2.5,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147344321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The More the Lipid-Lowering Agents, the Merrier: Welcome to Combination Therapy With Cholesteryl Ester Transfer Protein Inhibitors! 降脂剂越多越好：欢迎与胆固醇酯转移蛋白抑制剂联合治疗！

IF 2.2 4区医学

Journal of Cardiovascular Pharmacology Pub Date : 2026-04-01 DOI: 10.1097/FJC.0000000000001804

Giacomo Frati, Mariangela Peruzzi, Salvatore Giordano, Giuseppe Biondi-Zoccai

引用次数: 0